logo
episode-header-image
Aug 2023
7m 21s

322. Guidelines: 2021 ESC Cardiovascular...

CARDIONERDS
About this episode

The following question refers to Figures 6-8 from Sections 3.2 of the 2021 ESC CV Prevention Guidelines. The question is asked by student Dr. Hirsh Elhence, answered first by Ohio State University Cardiology Fellow Dr. Alli Bigeh, and then by expert faculty Dr. Eugene Yang.

Dr. Yang is Professor of Medicine at the University of Washington where he is also the Medical Director of the Eastside Specialty Center and the co-Director of the Cardiovascular Wellness and Prevention Program. Dr. Yang is former Governor of the ACC Washington Chapter and as well as former Chair of the ACC Prevention of CVD Section.  

The CardioNerds Decipher The Guidelines Series for the 2021 ESC CV Prevention Guidelines represents a collaboration with the ACC Prevention of CVD Section, the National Lipid Association, and Preventive Cardiovascular Nurses Association.

Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values.



Question #31

The 2021 ESC CV Prevention guidelines recommend a stepwise approach to risk stratification and treatment options. What is the first step in risk factor treatment regardless of past medical history, risk factors, or established ASCVD?

A

Initiate statin for goal LDL <100 mg/dl

B

Assess family history of premature CVD

C

Counsel on ketogenic diet

D

Stop smoking and lifestyle recommendations



Answer #31

Explanation

The correct answer is D – stop smoking and lifestyle recommendations. Smoking cessation and lifestyle modifications are recommended for everyone across the spectrum of ASCVD risk including for both primary and secondary prevention (Class 1). It is worth noting that many patients can move themselves towards a lower risk category without taking drugs just by stopping smoking.

Option A is incorrect. While initiating statin therapy for goal LDL <100 mg/dL may be an appropriate treatment option for some patients, it is not the first step per the “stepwise approach” recommended in the ESC guidelines. Whether or not to initiate a statin depends on a multitude of factors including estimated 10-year CVD risk, age, comorbidities, established ASCVD, and patient preference. The first step for patients with established ASCVD includes LDL-C reduction to goal <70 mg/dL (class I) with intensification to a goal LDL-C <55mg/dL based on residual 10-year CVD risk, lifetime CVD risk and treatment benefit, comorbidities, frailty, and patient preference.  Primary prevention of ASCVD first targets LDL-C goal <100 (class IIa) in appropriately selected patients.

Option B is incorrect. While assessing family history of premature CVD should be part of an initial evaluation and certainly considered a risk enhancing factor, it is not a modifiable risk factor with regards to treatment.

Option C is incorrect. A ketogenic diet is not endorsed nor recommended by ACC/AHA or ESC.

Studies have shown the benefit of a stepwise approach to treatment intensification. Attainment of treatment goals is similar, side effects are fewer, and patient satisfaction is significantly greater with such an approach. It is not recommended to stop assessment of treatment goals after the first step.

Main Takeaway

A stepwise approach to treatment intensification is recommended. The first steps for all patients are to stop smoking and institute lifestyle recommendations.

Guideline Loc.

·       3.2.3 Figures 6-8

CardioNerds Decipher the Guidelines – 2021 ESC Prevention Series
CardioNerds Episode Page
CardioNerds Academy
Cardionerds Healy Honor Roll

CardioNerds Journal Club
Subscribe to The Heartbeat Newsletter!
Check out CardioNerds SWAG!
Become a CardioNerds Patron!

Up next
Jul 10
421. Case Report: Switched at Birth: A Case of Congenital Heart Disease Presenting in Adulthood – New York Presbyterian Queens
CardioNerds (Dr. Claire Cambron and Dr. Rawan Amir) join Dr. Ayan Purkayastha, Dr. David Song, and Dr. Justin Wang from NewYork-Presbyterian Queens for an afternoon of hot pot in downtown Flushing. They discuss a case of congenital heart disease presenting in adulthood. Expert co ... Show More
29m 12s
Jun 20
420. Cardio-Rheumatology: Cardiovascular Multimodality Imaging & Systemic Inflammation with Dr. Monica Mukherjee
In this episode, CardioNerds Dr. Gurleen Kaur, Dr. Richard Ferraro, and Dr. Jake Roberts are joined by Cardio-Rheumatology expert, Dr. Monica Mukherjee, to discuss the role of utilizing multimodal imaging for cardiovascular disease risk stratification, monitoring, and management ... Show More
17m 54s
Jun 4
419. HFpEF in Women with Dr. Anu Lala and Dr. Martha Gulati
In this episode, CardioNerds Dr. Anna Radakrishnan and Dr. Apoorva Gangavelli are joined by prevention expert Dr. Martha Gulati and heart failure expert Dr. Anu Lala to discuss heart failure with preserved ejection fraction (HFpEF), a multifactorial, evolving challenge, particula ... Show More
24m 40s
Recommended Episodes
Jul 2022
USPSTF Recommendation: Behavioral Counseling Interventions to Promote Healthy Behaviors for CVD Prevention
Interview with Lori Pbert, PhD, USPSTF member and coauthor of Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors: US Preventive Services Task Force Recomme ... Show More
19m 55s
Feb 2024
Transatlantic Series with the ESVS: Intersocietal PAD Guidelines
Welcome to the Transatlantic series, a co-production of Audible Bleeding (a publication of the SVS) and the ESVS podcast. In today’s episode, we explore the intersocietal guidelines on peripheral arterial disease in patients with diabetes and foot ulcers authored by the Internati ... Show More
1h 9m
Apr 2023
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2023.1 Part 2
Dr. Dwight Owen is back on the ASCO Guidelines podcast, discussing the latest updates to the ASCO living guidelines for stage IV NSCLC. In Part 2, Dr. Owen presents the update for stage IV NSCLC with driver alterations. He reviews new evidence from KRYSTAL-1, and reviews a new re ... Show More
9m 21s
Jan 2024
Left Atrial Appendage Occlusion or Anticoagulation for Stroke Prevention in A Fib
Left Atrial Appendage Occlusion or Anticoagulation for Stroke Prevention in A Fib Guest: Mohamad Adnan (Mohamad) Alkhouli, M.D. Hosts: Malcolm R. Bell, M.D. In this podcast, we will discuss LAAO as an emerging method to reduce stroke risk in patients with atrial fibrillation. We ... Show More
14m 48s
Apr 2023
VTE Prophylaxis and Treatment in Patients with Cancer Guideline Update
Dr. Nigel Key and Dr. Anna Falanga join us for a conversation on the updated ASCO VTE prophylaxis and treatment in patients with cancer guideline. They discuss recent evidence assessing apixaban for VTE treatment in patients with cancer and evaluating direct factor Xa inhibitors ... Show More
14m 5s
Jun 2024
What’s Inside Your Coronary Arteries? with Anita Vadria, MS, PA-C (Episode 182)
Menopause and age raise our cardiovascular disease risk. Athletes and highly active people also tend to have a higher prevalence of coronary artery calcium and atherosclerotic plaque (though it tends to be the benign kind). But what does that all mean? How can we know what’s real ... Show More
45m 31s
Jun 2024
Episode 907: Wide-Complex Tachycardia
Contributor: Travis Barlock MD Educational Pearls: Wide-complex tachycardia is defined as a heart rate > 100 BPM with a QRS width > 120 milliseconds Wide-complex tachycardia of supraventricular origin is known as SVT with aberrancy Aberrancy is due to bundle branch blocks Mostly ... Show More
3m 46s
Jan 2024
Review of the Cardiac Arrhythmia Suppression Trial (CAST)
NEJM 1991;324:781-788Background A hallmark of post-myocardial infarction (MI) care in the 1980’s was the monitoring and suppression of premature ventricular contractions (PVCs) via use of antiarrhythmic drugs. The practice was based on pathophysiologic rationale that PVC burden i ... Show More
6m 58s
May 2024
All About Comparison ECGs for 12-Leads and Arrhythmias
All About Comparison ECGs for 12-Leads and Arrhythmias Guest: Ken Grauer, M.D. Host: Anthony H. Kashou, M.D.    In this episode, we explore the importance of clinically correlated ECGs, including the optimal techniques for ECG comparison, the role of clinical history in this proc ... Show More
35m 8s
May 2024
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.1
Dr. Jyoti Patel discusses the latest update to the stage IV NSCLC with driver alterations living guideline, specifically for patients with EGFR or ROS1 alterations. She shares the latest recommendations based on recently published evidence, such as the FLAURA2, MARIPOSA-2, and TR ... Show More
12m 24s